ECC 2015

25–29 September 2015 | Virtual Meeting

ECC 2015

25–29 September 2015 | Virtual Meeting
EURECCA international comparison of breast cancer treatment patterns 2:13
EURECCA international comparison of breast cancer treatment patterns
Riccardo Audisio • 26 Sep 2015
Molecular drivers of metastatic disease in breast cancer 1:20
Molecular drivers of metastatic disease in breast cancer
Giuseppe Curigliano • 26 Sep 2015
Post-diagnosis aspirin and survival in gastrointestinal cancers 4:25
Post-diagnosis aspirin and survival in gastrointestinal cancers
Martine Frouws • 25 Sep 2015
AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer 2:50
AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer
Eric Pujade-Lauraine • 26 Sep 2015
Emerging roles of nivolumab and cabozantinib for renal cell carcinoma 3:29
Emerging roles of nivolumab and cabozantinib for renal cell carcinoma
Thomas Powles • 25 Sep 2015
BELIEF: Phase 2 trial of erlotinib plus bevacizumab for non-small cell lung cancer 0:56
BELIEF: Phase 2 trial of erlotinib plus bevacizumab for non-small cell lung cancer
Bartomeu Massuti • 25 Sep 2015
Exploratory analysis of frontline therapies in REVEL: Phase 3 trial of ramucirumab in NSCLC 2:37
Exploratory analysis of frontline therapies in REVEL: Phase 3 trial of ramucirumab in NSCLC
Giorgio Scagliotti • 26 Sep 2015
TAILORx: Phase 3 trial validating a 21-gene expression assay in breast cancer 5:34
TAILORx: Phase 3 trial validating a 21-gene expression assay in breast cancer
Clifford Hudis • 25 Sep 2015
Changing the standard of care in previously treated metastatic renal cell carcinoma 2:31
Changing the standard of care in previously treated metastatic renal cell carcinoma
Laurence Albiges • 25 Sep 2015
Biomarker-directed, multi-drug, phase 1b trial in bladder cancer 1:25
Biomarker-directed, multi-drug, phase 1b trial in bladder cancer
Hendrik-Tobias Arkenau • 26 Sep 2015
Biomarker-driven therapies for triple-negative breast cancer 2:42
Biomarker-driven therapies for triple-negative breast cancer
Giuseppe Curigliano • 26 Sep 2015
CheckMate 025: Phase 3 trial of nivolumab for advanced kidney cancer 3:52
CheckMate 025: Phase 3 trial of nivolumab for advanced kidney cancer
Padmanee Sharma • 25 Sep 2015
Role of BRAF mutation in the treatment for melanoma 2:58
Role of BRAF mutation in the treatment for melanoma
Dirk Schadendorf • 26 Sep 2015

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals